Electroconvulsive therapy device classification: Response to FDA advisory panel hearing and recommendations

Richard Weiner, Sarah H. Lisanby, Mustafa M. Husain, Oscar G. Morales, Daniel F. Maixner, Stephen E. Hall, James Beeghly, John F. Greden

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Electroconvulsive therapy (ECT) is a safe and highly effective treatment for management of acute episodes of a variety of serious mental disorders, particularly for major depressive episodes that are resistant to multiple interventions with treatment alternatives. As such, the National Network of Depression Centers (NNDC), a consortium of major academic centers with interest and expertise in this area, believes there is an important public health need for ECT to remain available for clinical use. As with all medical devices, ECT is regulated by the US Food and Drug Administration (FDA), which is presently involved in formulating a proposed rule as to how such devices should be classified. Since such classification may have substantial effects on the availability of ECT to patients for whom it is clinically indicated, the NNDC has reviewed the information provided by the FDA to its Advisory Panel, as well as the subsequent deliberations of the Panel itself at a January 2011 public hearing. This review indicates that the FDA may have substantially underestimated the efficacy of ECT as a means to produce large clinical improvements for individuals suffering from severe major depressive disorders and that such an underestimate likely affected the Panel's willingness to recommend reclassification of ECT devices to a less restrictive category. In addition, the NNDC's review generates support for a variety of methods by which the safety of ECT can be ensured, which is an essential requirement for such reclassification.

Original languageEnglish (US)
Pages (from-to)38-42
Number of pages5
JournalJournal of Clinical Psychiatry
Volume74
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Electroconvulsive Therapy
United States Food and Drug Administration
Hearing
Equipment and Supplies
Depression
Major Depressive Disorder
Therapy
Food and Drug Administration
Mental Disorders
Public Health
Safety
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Arts and Humanities (miscellaneous)

Cite this

Electroconvulsive therapy device classification : Response to FDA advisory panel hearing and recommendations. / Weiner, Richard; Lisanby, Sarah H.; Husain, Mustafa M.; Morales, Oscar G.; Maixner, Daniel F.; Hall, Stephen E.; Beeghly, James; Greden, John F.

In: Journal of Clinical Psychiatry, Vol. 74, No. 1, 01.2013, p. 38-42.

Research output: Contribution to journalArticle

Weiner, Richard ; Lisanby, Sarah H. ; Husain, Mustafa M. ; Morales, Oscar G. ; Maixner, Daniel F. ; Hall, Stephen E. ; Beeghly, James ; Greden, John F. / Electroconvulsive therapy device classification : Response to FDA advisory panel hearing and recommendations. In: Journal of Clinical Psychiatry. 2013 ; Vol. 74, No. 1. pp. 38-42.
@article{75bb96bdbb724343875418c66c3e7a03,
title = "Electroconvulsive therapy device classification: Response to FDA advisory panel hearing and recommendations",
abstract = "Electroconvulsive therapy (ECT) is a safe and highly effective treatment for management of acute episodes of a variety of serious mental disorders, particularly for major depressive episodes that are resistant to multiple interventions with treatment alternatives. As such, the National Network of Depression Centers (NNDC), a consortium of major academic centers with interest and expertise in this area, believes there is an important public health need for ECT to remain available for clinical use. As with all medical devices, ECT is regulated by the US Food and Drug Administration (FDA), which is presently involved in formulating a proposed rule as to how such devices should be classified. Since such classification may have substantial effects on the availability of ECT to patients for whom it is clinically indicated, the NNDC has reviewed the information provided by the FDA to its Advisory Panel, as well as the subsequent deliberations of the Panel itself at a January 2011 public hearing. This review indicates that the FDA may have substantially underestimated the efficacy of ECT as a means to produce large clinical improvements for individuals suffering from severe major depressive disorders and that such an underestimate likely affected the Panel's willingness to recommend reclassification of ECT devices to a less restrictive category. In addition, the NNDC's review generates support for a variety of methods by which the safety of ECT can be ensured, which is an essential requirement for such reclassification.",
author = "Richard Weiner and Lisanby, {Sarah H.} and Husain, {Mustafa M.} and Morales, {Oscar G.} and Maixner, {Daniel F.} and Hall, {Stephen E.} and James Beeghly and Greden, {John F.}",
year = "2013",
month = "1",
doi = "10.4088/JCP.12cs08260",
language = "English (US)",
volume = "74",
pages = "38--42",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "1",

}

TY - JOUR

T1 - Electroconvulsive therapy device classification

T2 - Response to FDA advisory panel hearing and recommendations

AU - Weiner, Richard

AU - Lisanby, Sarah H.

AU - Husain, Mustafa M.

AU - Morales, Oscar G.

AU - Maixner, Daniel F.

AU - Hall, Stephen E.

AU - Beeghly, James

AU - Greden, John F.

PY - 2013/1

Y1 - 2013/1

N2 - Electroconvulsive therapy (ECT) is a safe and highly effective treatment for management of acute episodes of a variety of serious mental disorders, particularly for major depressive episodes that are resistant to multiple interventions with treatment alternatives. As such, the National Network of Depression Centers (NNDC), a consortium of major academic centers with interest and expertise in this area, believes there is an important public health need for ECT to remain available for clinical use. As with all medical devices, ECT is regulated by the US Food and Drug Administration (FDA), which is presently involved in formulating a proposed rule as to how such devices should be classified. Since such classification may have substantial effects on the availability of ECT to patients for whom it is clinically indicated, the NNDC has reviewed the information provided by the FDA to its Advisory Panel, as well as the subsequent deliberations of the Panel itself at a January 2011 public hearing. This review indicates that the FDA may have substantially underestimated the efficacy of ECT as a means to produce large clinical improvements for individuals suffering from severe major depressive disorders and that such an underestimate likely affected the Panel's willingness to recommend reclassification of ECT devices to a less restrictive category. In addition, the NNDC's review generates support for a variety of methods by which the safety of ECT can be ensured, which is an essential requirement for such reclassification.

AB - Electroconvulsive therapy (ECT) is a safe and highly effective treatment for management of acute episodes of a variety of serious mental disorders, particularly for major depressive episodes that are resistant to multiple interventions with treatment alternatives. As such, the National Network of Depression Centers (NNDC), a consortium of major academic centers with interest and expertise in this area, believes there is an important public health need for ECT to remain available for clinical use. As with all medical devices, ECT is regulated by the US Food and Drug Administration (FDA), which is presently involved in formulating a proposed rule as to how such devices should be classified. Since such classification may have substantial effects on the availability of ECT to patients for whom it is clinically indicated, the NNDC has reviewed the information provided by the FDA to its Advisory Panel, as well as the subsequent deliberations of the Panel itself at a January 2011 public hearing. This review indicates that the FDA may have substantially underestimated the efficacy of ECT as a means to produce large clinical improvements for individuals suffering from severe major depressive disorders and that such an underestimate likely affected the Panel's willingness to recommend reclassification of ECT devices to a less restrictive category. In addition, the NNDC's review generates support for a variety of methods by which the safety of ECT can be ensured, which is an essential requirement for such reclassification.

UR - http://www.scopus.com/inward/record.url?scp=84873858662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873858662&partnerID=8YFLogxK

U2 - 10.4088/JCP.12cs08260

DO - 10.4088/JCP.12cs08260

M3 - Article

C2 - 23419224

AN - SCOPUS:84873858662

VL - 74

SP - 38

EP - 42

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 1

ER -